Physician profile

Charles Edge

Family · Atlanta, GA

NPI 1568986313

$1,742.16

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,158.45

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Viiv Healthcare Company $526.73 2022-2024 Dovato
Impel Pharmaceuticals INC. $289.76 2022-2023 Trudhesa
Coloplast Corp $253.13 2022-2023 Titan, Altis
Janssen Pharmaceuticals, INC $135.00 2022
Teva Pharmaceuticals USA, INC. $124.41 2023 Austedo Xr
Scpharmaceuticals INC. $124.03 2024
Otsuka America Pharmaceutical, INC. $116.25 2023 Rexulti
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $94.41 2023
Gilead Sciences, INC. $78.44 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Charles Edge

$1,742.16

in general payments reported 2019-2025

Years
2022-2024
Top company
Viiv Healthcare Company

https://glasscript.com/doctor/10460817/charles-edge

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.